Leykostim (Leucostim) - this preparation sold as a solution for intravenous and subcutaneous administration. It refers to the pharmacological group "leykopoeza stimulant."
The active ingredient of the drug is filgrastim, representing a recombinant granulocyte colony stimulating factor. One ml of the solution can contain 150 g (15 ppm. I.U.) filgrastim or 300 mcg (30 MIU).
Product form - package comprising one or five vials Leykostima.
Pharmacological properties Leykostima
Leykostim is a drug-immunomodulator. Not representing a highly glycosylated protein has a regulating effect on the production of functional neutrophils, as well as their movement from the bone marrow into the blood. It contributes to a significant increase in the number of neutrophils within 24 hours of taking the drug also increases the number of monocytes (slightly). The increase in the number of neutrophils in the blood is dose-dependent.
Production of filgrastim - biologically active protein, normalizing the differentiation and proliferation of cells - is carried out by bacterial strain Escherichia coli, augmented thanks to the possibilities of genetic engineering, gene of human granulocyte colony stimulating factor. According to its effects on the body similar to Leykostim granulocyte colony stimulating factor of natural origin. The only difference Leykostim not glycosylated and has an additional N-terminal methionine amino acid residue.
Leykostim drug is useful for a diagnosis of neutropenia in patients undergoing chemotherapy, as well as neutropenia, which flows in the chronic form, since it helps to restore the optimal number of neutrophils in the body. The received prophylactic, it helps to reduce the incidence of neutropenia, the complexity of the course and duration of the disease. This, in turn, prevents the development of complications of an infectious nature, reduces the duration of hospitalization, allows chemotherapy, without deviating from the terms established by the general scheme of treatment.
The instructions to Leykostimu indicated that the use of this drug helps to mobilize to peripheral blood cells prior hematopoiesis, who are going through cytapheresis method (method of separation of the cellular elements of blood on their selective removal) and administered to the patient after he passed a course of high dose chemotherapy. The entered stem cells with hematopoietic function, allow you to restore the immune system and the hematopoietic system after chemotherapy, as well as reduce the risk of and severity of bleeding complications and complications of an infectious nature.
Leykostim is equally safe for patients undergoing cytotoxic chemotherapy, for both adults and children.
People with immunodeficiency virus the drug maintains an optimum level of neutrophils and, as a consequence, the ability to follow the recommended doses of antiretroviral therapy and / or other myelosuppressive therapy. When applying filgrastim increase HIV replication was observed.
Leykostima concentration of active substance in the blood plasma is directly dependent on the dose administered to the patient. After subcutaneous or intravenous administration half-life of filgrastim body is three to four hours.
In the process of metabolism filgrastim is converted into peptides and small part of it remained unchanged (no more than 1% of the administered drug), excreted from the body in the urine.
Chronic administration Leykostima when treatment comes to 28 days, the accumulation of filgrastim is not happening. The half-life remains unchanged.
According to the instructions Leykostimu, identify the following objectives prescribing:
- reduction in the duration of neutropenia flow II-IV stages, reducing the frequency of symptoms of febrile neutropenia in patients with tumors nemieloproliferativnymi after passing a course of chemotherapy with cytotoxic drugs;
- mobilization of hematopoietic progenitor cells into the peripheral blood to allow them to separate and transplanted after myelosuppressive chemotherapy;
- reduce the appearance of complications arising from neutropenia, as well as reducing the time course of the disease in patients undergoing myeloablative chemotherapy with the need for future bone marrow transplantation;
- treatment of chronic neutropenia;
- treatment of neutropenia in patients with HIV infection in the developed stage in order to reduce the risk of infections of bacterial origin;
- mobilization of hematopoietic progenitor cells into the peripheral blood of healthy donors to allow them to separate and transplant patients.
- at elevated individual sensitivity to its active ingredient, and other ingredients;
- if there is a congenital severe neutropenia (Kostmann's syndrome), which flows from the cytogenetic violations;
- newborn babies (first 28 days of life).
Instructions Leykostima: Dosage and administration
Leykostim introduced in two ways:
The route of administration and dosage are set by the attending physician, depending on the individual patient and the nature of the disease.
The most optimal is a subcutaneous Leykostima.
If desired drug administered intravenously, it is taken by syringe from the vial and placed in a vial / container with a 5% dextrose solution. Then, for 30 minutes produces an infusion of diluted drug.
Leykostim appoint not less than 24 hours before the start of chemotherapy and not earlier than 24 hours after the end of its course.
Admission during pregnancy and lactation
Effect of the drug has not been studied in pregnant women, so data on its safety for this group by far not. Therefore Leykostim recommended the appointment during pregnancy.
If you want to receive Leykostima during lactation, breast-feeding should be discontinued.
Side effects and overdose Leykostimom
Cases of overdose Leykostimom not observed.
With the introduction of the drug in recommended doses may be pain at the injection site, pain in bones and muscles.
Subject to temperature (optimally 2-8 ° C) Leykostim fit for use for 2 years.